Literature DB >> 22548014

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Christopher G Azzoli1, Sarah Temin, Giuseppe Giaccone.   

Abstract

ASCO produced the 2011 Focused Update based on phase III randomized clinical trials published on maintenance chemotherapy, addressing one question from the 2009 Guideline Update on chemotherapy for stage IV NSCLC: what is the optimal duration of first-line chemotherapy for stage IV NSCLC?

Entities:  

Year:  2011        PMID： 22548014      PMCID： PMC3266319          DOI： 10.1200/JOP.2011.000374

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  2 in total

1.  2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Authors:  Christopher G Azzoli; Sarah Temin; Timothy Aliff; Sherman Baker; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; William Pao; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

2.  American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Authors:  Christopher G Azzoli; Sherman Baker; Sarah Temin; William Pao; Timothy Aliff; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544
  2 in total
  36 in total

1.  Cancer-related inflammation as predicting tool for treatment outcome in locally advanced and metastatic non-small cell lung cancer.

Authors:  Sonja Badovinac; Marta Korsic; Davorka Mursic; Miroslav Samarzija; Branka Cucevic; Mihovil Roglic; Marko Jakopovic
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.

Authors:  Mei Ji; Yan Liu; Qing Li; Xiaodong Li; Zhonghua Ning; Weiqing Zhao; Hongbing Shi; Jingting Jiang; Changping Wu
Journal:  Cancer Biol Ther       Date:  2016-03-08       Impact factor: 4.742

3.  Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer.

Authors:  Kyoichi Kaira; Noriko Yanagitani; Noriaki Sunaga; Hisao Imai; Akihiro Ono; Yasuhiko Koga; Takeshi Hisada; Tamotsu Ishizuka; Masanobu Yamada
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

4.  Factors influencing treatment selection and survival in advanced lung cancer.

Authors:  S Tabchi; E Kassouf; M Florescu; M Tehfe; N Blais
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

5.  Exercise and nutrition interventions in advanced lung cancer: a systematic review.

Authors:  C Payne; P J Larkin; S McIlfatrick; L Dunwoody; J H Gracey
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

6.  Lung cancer. How much platinum-based chemotherapy is enough in NSCLC?

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2014-12-02       Impact factor: 66.675

7.  Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing.

Authors:  Kumar Prabhash; Suresh H Advani; Ullas Batra; Bivas Biswas; Anuradha Chougule; Mithua Ghosh; Vamshi Krishna Muddu; T P Sahoo; Ashok K Vaid
Journal:  Adv Ther       Date:  2019-03-12       Impact factor: 3.845

Review 8.  Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents.

Authors:  Eamon M Berge; Robert C Doebele
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells.

Authors:  Huan Wang; Xiaoli Zhu; Jing Huang; Pingsheng Chen; Shuhua Han; Xing Yan
Journal:  Oncol Lett       Date:  2016-02-24       Impact factor: 2.967

10.  Harnessing Clinical Sequencing Data for Survival Stratification of Patients with Metastatic Lung Adenocarcinomas.

Authors:  Ronglai Shen; Axel Martin; Ai Ni; Matthew Hellmann; Kathryn C Arbour; Emmet Jordan; Arshi Arora; Ryan Ptashkin; Ahmet Zehir; Mark G Kris; Charles M Rudin; Michael F Berger; David B Solit; Venkatraman E Seshan; Maria Arcila; Marc Ladanyi; Gregory J Riely
Journal:  JCO Precis Oncol       Date:  2019-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.